Trinity Biotech (TRIB) Competitors $0.58 -0.06 (-8.74%) As of 11:10 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRIB vs. VRCA, OTLK, ATNM, RPTX, IBIO, NBRV, KZR, SPRO, CELU, and CNTBShould you be buying Trinity Biotech stock or one of its competitors? The main competitors of Trinity Biotech include Verrica Pharmaceuticals (VRCA), Outlook Therapeutics (OTLK), Actinium Pharmaceuticals (ATNM), Repare Therapeutics (RPTX), iBio (IBIO), Nabriva Therapeutics (NBRV), Kezar Life Sciences (KZR), Spero Therapeutics (SPRO), Celularity (CELU), and Connect Biopharma (CNTB). These companies are all part of the "pharmaceutical products" industry. Trinity Biotech vs. Verrica Pharmaceuticals Outlook Therapeutics Actinium Pharmaceuticals Repare Therapeutics iBio Nabriva Therapeutics Kezar Life Sciences Spero Therapeutics Celularity Connect Biopharma Verrica Pharmaceuticals (NASDAQ:VRCA) and Trinity Biotech (NASDAQ:TRIB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment. Is VRCA or TRIB more profitable? Trinity Biotech has a net margin of -34.39% compared to Verrica Pharmaceuticals' net margin of -625.06%. Trinity Biotech's return on equity of 0.00% beat Verrica Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Verrica Pharmaceuticals-625.06% -591.84% -141.63% Trinity Biotech -34.39%N/A -21.37% Do insiders & institutionals believe in VRCA or TRIB? 42.5% of Verrica Pharmaceuticals shares are held by institutional investors. Comparatively, 79.0% of Trinity Biotech shares are held by institutional investors. 42.6% of Verrica Pharmaceuticals shares are held by insiders. Comparatively, 8.2% of Trinity Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has better earnings and valuation, VRCA or TRIB? Trinity Biotech has higher revenue and earnings than Verrica Pharmaceuticals. Trinity Biotech is trading at a lower price-to-earnings ratio than Verrica Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVerrica Pharmaceuticals$7.57M4.79-$67M-$1.54-0.26Trinity Biotech$59.13M0.18-$24.02M-$2.26-0.26 Which has more risk & volatility, VRCA or TRIB? Verrica Pharmaceuticals has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500. Comparatively, Trinity Biotech has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Do analysts prefer VRCA or TRIB? Verrica Pharmaceuticals presently has a consensus target price of $9.50, suggesting a potential upside of 2,305.06%. Given Verrica Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Verrica Pharmaceuticals is more favorable than Trinity Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verrica Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20Trinity Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor VRCA or TRIB? In the previous week, Verrica Pharmaceuticals had 4 more articles in the media than Trinity Biotech. MarketBeat recorded 6 mentions for Verrica Pharmaceuticals and 2 mentions for Trinity Biotech. Trinity Biotech's average media sentiment score of 0.62 beat Verrica Pharmaceuticals' score of 0.38 indicating that Trinity Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verrica Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Trinity Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community favor VRCA or TRIB? Trinity Biotech received 168 more outperform votes than Verrica Pharmaceuticals when rated by MarketBeat users. Likewise, 70.82% of users gave Trinity Biotech an outperform vote while only 63.74% of users gave Verrica Pharmaceuticals an outperform vote. CompanyUnderperformOutperformVerrica PharmaceuticalsOutperform Votes16763.74% Underperform Votes9536.26% Trinity BiotechOutperform Votes33570.82% Underperform Votes13829.18% SummaryVerrica Pharmaceuticals and Trinity Biotech tied by winning 9 of the 18 factors compared between the two stocks. Remove Ads Get Trinity Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for TRIB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRIB vs. The Competition Export to ExcelMetricTrinity BiotechDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.56M$2.42B$5.61B$7.68BDividend YieldN/A0.72%5.33%4.02%P/E Ratio-0.266.1123.5018.55Price / Sales0.1844.10376.0088.66Price / CashN/A15.7538.1734.64Price / Book-0.192.946.814.11Net Income-$24.02M-$65.73M$3.20B$247.18M7 Day Performance-11.95%-7.74%-5.42%-4.05%1 Month Performance-19.97%-11.54%-0.12%-6.41%1 Year Performance-71.32%-22.65%7.61%-2.08% Trinity Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRIBTrinity Biotech1.5097 of 5 stars$0.59-8.7%N/A-67.5%$10.56M$59.13M-0.26480Upcoming EarningsAnalyst ForecastVRCAVerrica Pharmaceuticals4.1558 of 5 stars$0.52-6.4%$9.50+1,719.6%-92.7%$47.92M$7.57M-0.2940OTLKOutlook Therapeutics1.5538 of 5 stars$1.50-1.0%$10.20+582.3%-88.9%$47.87MN/A-0.2020Positive NewsATNMActinium Pharmaceuticals1.7557 of 5 stars$1.49-3.9%$7.40+396.6%N/A$46.48M$81,000.00-1.0730Analyst RevisionNews CoverageGap DownHigh Trading VolumeRPTXRepare Therapeutics3.3867 of 5 stars$1.08-3.6%$4.50+316.7%-77.7%$45.91M$53.48M-0.54180IBIOiBio0.5635 of 5 stars$4.63flat$4.30-7.1%+1.5%$45.72M$375,000.000.00100Positive NewsGap UpNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070KZRKezar Life Sciences4.1093 of 5 stars$6.16+4.6%$39.50+541.2%-45.4%$44.94M$7M-0.4760Earnings ReportShort Interest ↑Analyst RevisionSPROSpero Therapeutics4.306 of 5 stars$0.82-0.6%$5.00+511.6%-55.2%$44.57M$89.87M11.68150Earnings ReportHigh Trading VolumeCELUCelularity0.318 of 5 stars$1.87+2.7%N/A-66.1%$44.52M$48.20M0.00220Short Interest ↑CNTBConnect Biopharma3.3633 of 5 stars$0.80-1.8%$8.00+900.0%-60.9%$44.20M$24.12M0.00110News Coverage Remove Ads Related Companies and Tools Related Companies Verrica Pharmaceuticals Competitors Outlook Therapeutics Competitors Actinium Pharmaceuticals Competitors Repare Therapeutics Competitors iBio Competitors Nabriva Therapeutics Competitors Kezar Life Sciences Competitors Spero Therapeutics Competitors Celularity Competitors Connect Biopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRIB) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trinity Biotech plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Trinity Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TRIB Stock Free TRIB Stock Alerts